Dr. Pediaditakis is the Associate Director of Neuroscience at Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies. Prior to joining Alchemab, he was the Associate Director of Complex Physiological Systems at Vesalius Therapeutics, where he led the development, design, and implementation of new human cell-based complex in vitro models in the preclinical stage of drug development. Before joining Vesalius, Dr. Pediaditakis was Associate Director of Research at Emulate Inc., a Harvard spinoff. He led the neuroscience team to develop next-generation tissue chip models of neuroinflammation and Parkinson's disease. He utilized induced pluripotent stem cells to incorporate blood vessel cells, neurons, astrocytes, and microglia into perfuseable micro-engineered 3D environments to model human brain function, blood-brain barrier physiology and uncover novel biomarkers of neurodegenerative diseases. Prior to Emulate, Dr. Pediaditakis completed his postdoctoral fellowship at the Medical School of the University of Crete and the Institute of the Foundation for Research and Technology-Hellas, where he spearheaded the development of a new family of synthetic, BBB-permeable neurotrophic receptor agonists as a potential treatment for a wide range of neurological disorders, including ALS, Alzheimer's, and Parkinson's disease. Dr. Pediaditakis has broad expertise in neuropharmacology and Organs-on-Chips technology.
-The human Brain-Chip Dr. Pediaditakis developed at Emulate Inc was recognized as one of The Scientist's Top 10 Innovations of 2021.
-Dr. Pediaditakis has been named as one of Greek America's Forty Under 40 for the Class of 2022.
